OOIR: Observatory of International Research

Papers

(The H4-Index of Transfusion is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Prepare to adapt: blood supply and transfusion support during the first 2 weeks of the 2019 novel coronavirus (COVID‐19) pandemic affecting Washington State	129
COVID‐19 and ABO blood groups	78
SARS‐CoV‐2 asymptomatic and symptomatic patients and risk for transfusion transmission	67
Use of convalescent plasma inCOVID‐19 patients with immunosuppression	64
Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program	54
Characteristics and serological patterns of COVID‐19 convalescent plasma donors: optimal donors and timing of donation	51
SARS‐CoV‐2 seroprevalence among blood donors after the first COVID‐19 wave in Canada	45
The use of low‐titer group O whole blood is independently associated with improved survival compared to component therapy in adults with severe traumatic hemorrhage	44
Has the trend of declining blood transfusions in the United States ended? Findings of the 2019 National Blood Collection and Utilization Survey	43
COVID‐19 associated with severe autoimmune hemolytic anemia	41
SARS‐CoV‐2 antibody persistence in COVID‐19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance	41
Correlation between SARS‐COV‐2 antibody screening by immunoassay and neutralizing antibody testing	41
Therapeutic plasma exchange for COVID‐19‐associated hyperviscosity	40
COVID‐19 convalescent plasma: Interim recommendations from the AABB	38
Risk of transmission of severe acute respiratory syndrome coronavirus 2 by transfusion: A literature review	36
Survey of group A plasma and low‐titer group O whole blood use in trauma resuscitation at adult civilian level 1 trauma centers in the US	36
Supply and demand for plasma‐derived medicinal products ‐ A critical reassessment amid the COVID‐19 pandemic	36
Production of anti‐SARS‐CoV‐2 hyperimmune globulin from convalescent plasma	36
Blood transfusion utilization in hospitalized COVID‐19 patients	36
How did we rapidly implement a convalescent plasma program?	35
Is SARS‐CoV‐2 transfusion transmitted?	35
Expansion of hospital‐based blood collections in the face of COVID‐19 associated national blood shortage	34
Nicotine exposure increases markers of oxidant stress in stored red blood cells from healthy donor volunteers	33
Convalescent plasma to treat coronavirus disease 2019 (COVID‐19): considerations for clinical trial design	33
Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light	33

Exploring predictors of Australian community members' blood donation intentions and blood donation–related behavior during the COVID‐19 pandemic	33
How do I manage severe postpartum hemorrhage?	33
Prehospital whole blood reduces early mortality in patients with hemorrhagic shock	33
Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia—A systematic review and meta‐analysis	32
Association of ABO blood group and secretor phenotype with severe COVID‐19	32
Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: A systematic review and meta‐analysis	32